[
  {
    "ts": "2025-12-16T13:00:00+00:00",
    "headline": "Cradle AI-powered protein engineering platform serving six of top 25 pharma leaders",
    "summary": "Cradle, an enterprise-grade AI software platform, today announced a series of milestones that signal a new phase of growth. The company saw rapid adoption across the pharma industry, with Cradle now running 50+ projects and powering drug discovery programs for six of the top 25 big pharma companies, including Johnson & Johnson, Abbvie, and Novo Nordisk. To continue expanding product capabilities and meet surging global demand, the company has doubled headcount across all departments and expanded",
    "url": "https://finance.yahoo.com/news/cradle-ai-powered-protein-engineering-130000674.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "2b5e2404-deba-30dd-b78e-a266f3a1eea7",
      "content": {
        "id": "2b5e2404-deba-30dd-b78e-a266f3a1eea7",
        "contentType": "STORY",
        "title": "Cradle AI-powered protein engineering platform serving six of top 25 pharma leaders",
        "description": "",
        "summary": "Cradle, an enterprise-grade AI software platform, today announced a series of milestones that signal a new phase of growth. The company saw rapid adoption across the pharma industry, with Cradle now running 50+ projects and powering drug discovery programs for six of the top 25 big pharma companies, including Johnson & Johnson, Abbvie, and Novo Nordisk. To continue expanding product capabilities and meet surging global demand, the company has doubled headcount across all departments and expanded",
        "pubDate": "2025-12-16T13:00:00Z",
        "displayTime": "2025-12-16T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/fc40123aaedbadb35b9ad3d93071a1c0",
          "originalWidth": 400,
          "originalHeight": 121,
          "caption": "Cradle",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rYz7kD7r_0_sMNyo5ZE5Cw--~B/aD0xMjE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/fc40123aaedbadb35b9ad3d93071a1c0.cf.webp",
              "width": 400,
              "height": 121,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J2JpHMYTHST9tL2siQaBYw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/fc40123aaedbadb35b9ad3d93071a1c0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cradle-ai-powered-protein-engineering-130000674.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cradle-ai-powered-protein-engineering-130000674.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-16T14:35:07+00:00",
    "headline": "AbbVie price target lowered to $233 from $248 at BofA",
    "summary": "BofA lowered the firm’s price target on AbbVie (ABBV) to $233 from $248 and keeps a Neutral rating on the shares. The firm, which sees “a relatively clean setup” for growth at the high end of the peer group being balanced by a premium multiple and limited late-stage pipeline catalysts, is shifting its valuation basis to its FY27 estimates.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper",
    "url": "https://finance.yahoo.com/news/abbvie-price-target-lowered-233-143507067.html",
    "source": "TipRanks",
    "provider": "yfinance",
    "raw": {
      "id": "cdc58bd3-c7a0-34d3-ac74-a3a4d0f64eed",
      "content": {
        "id": "cdc58bd3-c7a0-34d3-ac74-a3a4d0f64eed",
        "contentType": "STORY",
        "title": "AbbVie price target lowered to $233 from $248 at BofA",
        "description": "",
        "summary": "BofA lowered the firm’s price target on AbbVie (ABBV) to $233 from $248 and keeps a Neutral rating on the shares. The firm, which sees “a relatively clean setup” for growth at the high end of the peer group being balanced by a premium multiple and limited late-stage pipeline catalysts, is shifting its valuation basis to its FY27 estimates.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper",
        "pubDate": "2025-12-16T14:35:07Z",
        "displayTime": "2025-12-16T14:35:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/tipranks_452/66c6590c94d0f93ba894c14d0895690d",
          "originalWidth": 192,
          "originalHeight": 192,
          "caption": "https://www.tipranks.com/news/the-fly/abbvie-price-target-lowered-to-233-from-248-at-bofa-thefly",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/m6ibw8wTOutmCnQKc3D.JQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/66c6590c94d0f93ba894c14d0895690d.cf.webp",
              "width": 192,
              "height": 192,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NaD9ymG69w04qqwH8CEn_w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/66c6590c94d0f93ba894c14d0895690d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TipRanks",
          "url": "https://www.tipranks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-price-target-lowered-233-143507067.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-price-target-lowered-233-143507067.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]